{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:44:37Z","timestamp":1790775877507,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00406-019-01060-7","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T09:08:41Z","timestamp":1566551321000},"page":"35-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Severe parkinsonism under treatment with antipsychotic drugs"],"prefix":"10.1007","volume":"270","author":[{"given":"Katrin","family":"Druschky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf R.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Neyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"D\u00e4ubl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"St\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1017\/S003329170003960X","volume":"10","author":"CD Marsden","year":"1980","unstructured":"Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55\u201372. \nhttps:\/\/doi.org\/10.1017\/S003329170003960X","journal-title":"Psychol Med"},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/mds.26839","volume":"32","author":"R Savica","year":"2017","unstructured":"Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA (2017) Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord 32:227\u2013234. \nhttps:\/\/doi.org\/10.1002\/mds.26839","journal-title":"Mov Disord"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.1956.02970030032008","volume":"161","author":"RA Hall","year":"1956","unstructured":"Hall RA, Jackson RB, Swain JM (1956) Neurotoxic reactions resulting from chlorpromazine administration. J Am Med Assoc 161:214\u2013218. \nhttps:\/\/doi.org\/10.1001\/jama.1956.02970030032008","journal-title":"J Am Med Assoc"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/s-2000-7660","volume":"33","author":"J Horacek","year":"2000","unstructured":"Horacek J (2000) Novel antipsychotics and extrapyramidal side effects. Theory Real Pharmacopsychiatry 33:34\u201342. \nhttps:\/\/doi.org\/10.1055\/s-2000-7660","journal-title":"Theory Real Pharmacopsychiatry"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3349\/ymj.1993.34.2.179","volume":"34","author":"SK Min","year":"1993","unstructured":"Min SK, Rhee CS, Kim CE, Kang DY (1993) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 34:179\u2013190. \nhttps:\/\/doi.org\/10.3349\/ymj.1993.34.2.179","journal-title":"Yonsei Med J"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4088\/JCP.v59n0205","volume":"59","author":"CH Miller","year":"1998","unstructured":"Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA (1998) The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 59:69\u201375. \nhttps:\/\/doi.org\/10.4088\/JCP.v59n0205","journal-title":"J Clin Psychiatry"},{"key":"1060_CR7","first-page":"CDD51334","volume":"4","author":"CE Adams","year":"2003","unstructured":"Adams CE, Coutinho E, Duggan L, Gilbody S, Leucht S, Wahlbeck K (2003) Cochrane schizophrenia group. Cochrane Database Syst Rev 4:CDD51334","journal-title":"Cochrane Database Syst Rev"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, H\u00f6schl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389\u2013409","journal-title":"CNS Drugs"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1472-8206.2000.tb00437.x","volume":"14","author":"SK Kulkarni","year":"2000","unstructured":"Kulkarni SK, Ninan I (2000) Dopamine D4 receptors and development of newer antipsychotic drugs. Fundam Clin Pharmacol 14:529\u2013539","journal-title":"Fundam Clin Pharmacol"},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.pnpbp.2003.09.005","volume":"27","author":"AH Wong","year":"2003","unstructured":"Wong AH, Van Tol HH (2003) The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1091\u20131099","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s002280100302","volume":"57","author":"I Schillevoort","year":"2001","unstructured":"Schillevoort I, de Boer A, Herings RM, Roos RA, Jansen PA, Leufkens HG (2001) Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol 57:327\u2013331. \nhttps:\/\/doi.org\/10.1007\/s002280100302","journal-title":"Eur J Clin Pharmacol"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","volume":"88","author":"OJ Hoyberg","year":"1993","unstructured":"Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 88:395\u2013402. \nhttps:\/\/doi.org\/10.1111\/j.1600-0447.1993.tb03480.x","journal-title":"Acta Psychiatr Scand"},{"key":"1060_CR13","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1212\/WNL.52.4.782","volume":"52","author":"PI Rosebush","year":"1999","unstructured":"Rosebush PI, Mazurek MF (1999) Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52:782\u2013785. \nhttps:\/\/doi.org\/10.1212\/WNL.52.4.782","journal-title":"Neurology"},{"key":"1060_CR14","first-page":"73","volume":"280","author":"G Perrault","year":"1997","unstructured":"Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997) Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73\u201382","journal-title":"J Pharmacol Exp Ther"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","volume":"16","author":"D Tarsy","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23\u201345. \nhttps:\/\/doi.org\/10.2165\/00023210-200216010-00003","journal-title":"CNS Drugs"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/pgmj.2008.073312","volume":"85","author":"B Thanvi","year":"2009","unstructured":"Thanvi B, Treadwell S (2009) Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 85:322\u2013326. \nhttps:\/\/doi.org\/10.1136\/pgmj.2008.073312","journal-title":"Postgrad Med J"},{"key":"1060_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","volume":"15","author":"EW Tuplin","year":"2017","unstructured":"Tuplin EW, Holahan MR (2017) Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol 15:1192\u20131207. \nhttps:\/\/doi.org\/10.2174\/1570159X15666170413115754","journal-title":"Curr Neuropharmacol"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1055\/s-2004-815505","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, Ruther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37:S4\u2013S11. \nhttps:\/\/doi.org\/10.1055\/s-2004-815505","journal-title":"Pharmacopsychiatry"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00406-013-0419-y","volume":"264","author":"R Grohmann","year":"2014","unstructured":"Grohmann R, Engel RR, Moller HJ, Ruther E, van der Velden JW, Stubner S (2014) Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci 264:131\u2013141. \nhttps:\/\/doi.org\/10.1007\/s00406-013-0419-y","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","volume":"51","author":"WR Gibb","year":"1988","unstructured":"Gibb WR, Lees AJ (1988) The relevance of the lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 51:745\u2013752. \nhttps:\/\/doi.org\/10.1136\/jnnp.51.6.745","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.1.5643.531","volume":"1","author":"N Hurwitz","year":"1969","unstructured":"Hurwitz N, Wade OL (1969) Intensive hospital monitoring of adverse reactions to drugs. Br Med J 1:531\u2013536. \nhttps:\/\/doi.org\/10.1136\/bmj.1.5643.531","journal-title":"Br Med J"},{"key":"1060_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2105\/AJPH.55.8.1170","volume":"55","author":"LG Seidl","year":"1965","unstructured":"Seidl LG, Thornton GF, Cluff LE (1965) Epidemiological studies of adverse drug reactions. Am J Public Health Nations Health 55:1170\u20131175. \nhttps:\/\/doi.org\/10.2105\/AJPH.55.8.1170","journal-title":"Am J Public Health Nations Health"},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2307\/2331986","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404\u2013413. \nhttps:\/\/doi.org\/10.2307\/2331986","journal-title":"Biometrika"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/sim.4780120902","volume":"12","author":"SE Vollset","year":"1993","unstructured":"Vollset SE (1993) Confidence intervals for a binomial proportion. Stat Med 12:809\u2013824. \nhttps:\/\/doi.org\/10.1002\/sim.4780120902","journal-title":"Stat Med"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00115-004-1831-3","volume":"76","author":"E Lambreva","year":"2005","unstructured":"Lambreva E, Vecellio M, Wieser HG, Buddeberg C (2005) Neurotoxic encephalopathy caused by neuroleptics and lithium. Nervenarzt 76:756\u2013759","journal-title":"Nervenarzt"},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0010-440X(82)90049-9","volume":"23","author":"R Prakash","year":"1982","unstructured":"Prakash R, Kelwala S, Ban TA (1982) Neurotoxicity with combined administration of lithium and a neuroleptic. Compr Psychiatry 23:567\u2013571","journal-title":"Compr Psychiatry"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, Wahlbeck K (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 161:160\u2013163. \nhttps:\/\/doi.org\/10.1176\/appi.ajp.161.1.160","journal-title":"Am J Psychiatry"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ageing\/18.3.208","volume":"18","author":"JA Wilson","year":"1989","unstructured":"Wilson JA, MacLennan WJ (1989) Review: drug-induced parkinsonism in elderly patients. Age Ageing 18:208\u2013210. \nhttps:\/\/doi.org\/10.1093\/ageing\/18.3.208","journal-title":"Age Ageing"},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1055\/s-2004-815511","volume":"37","author":"S Stubner","year":"2004","unstructured":"Stubner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundorfer G, Moller HJ, Hippius H, Ruther E (2004) Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 37:S54\u2013S64. \nhttps:\/\/doi.org\/10.1055\/s-2004-815511","journal-title":"Pharmacopsychiatry"},{"key":"1060_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"HW Shin","year":"2012","unstructured":"Shin HW, Chung SJ (2012) Drug-induced parkinsonism. J Clin Neurol 8:15\u201321. \nhttps:\/\/doi.org\/10.3988\/jcn.2012.8.1.15","journal-title":"J Clin Neurol"},{"key":"1060_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0072-9752(07)84051-6","volume":"84","author":"FE Micheli","year":"2007","unstructured":"Micheli FE, Cersosimo MG (2007) Drug-induced parkinsonism. Handb Clin Neurol 84:399\u2013416. \nhttps:\/\/doi.org\/10.1016\/S0072-9752(07)84051-6","journal-title":"Handb Clin Neurol"},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/1531-8257(199901)14:1<128::AID-MDS1021>3.0.CO;2-J","volume":"14","author":"G Lera","year":"1999","unstructured":"Lera G, Zirulnik J (1999) Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 14:128\u2013131. \nhttps:\/\/doi.org\/10.1002\/1531-8257(199901)14:1%3c128:AID-MDS1021%3e3.0.CO;2-J","journal-title":"Mov Disord"},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JCP.0b013e318166c4d5","volume":"28","author":"K Gao","year":"2008","unstructured":"Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28:203\u2013209. \nhttps:\/\/doi.org\/10.1097\/JCP.0b013e318166c4d5","journal-title":"J Clin Psychopharmacol"},{"key":"1060_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0002-9343(99)80104-1","volume":"99","author":"J Avorn","year":"1995","unstructured":"Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, Walker A (1995) Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 99:48\u201354. \nhttps:\/\/doi.org\/10.1016\/S0002-9343(99)80104-1","journal-title":"Am J Med"},{"key":"1060_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/00048674.2010.538839","volume":"45","author":"YT Xiang","year":"2011","unstructured":"Xiang YT, Wang CY, Si TM et al (2011) Sex differences in use of psychotropic drugs and drug-induced side effects in schizophrenia patients: findings of the research on Asia psychotropic prescription (REAP) studies. Aust N Z J Psychiatry 45:193\u2013198. \nhttps:\/\/doi.org\/10.3109\/00048674.2010.538839","journal-title":"Aust N Z J Psychiatry"},{"key":"1060_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15622975.2018.1500030","volume":"15","author":"K Druschky","year":"2018","unstructured":"Druschky K, Bleich S, Grohmann R, Engel RR, Neyazi A, Stubner S, Toto S (2018) Seizure rates under treatment with antipsychotic drugs: data from the AMSP project. World J Biol Psychiatry 15:1\u201310. \nhttps:\/\/doi.org\/10.1080\/15622975.2018.1500030","journal-title":"World J Biol Psychiatry"},{"key":"1060_CR37","unstructured":"Friedrich ME, Grohmann R, Rabl U, Winkler D, Konstantinidis A, Engel R, Toto S, St\u00fcbner S, Frey R, Kasper S Incidence rates of CNS drug-induced delirium\u2014a drug surveillance report of German-speaking countries between 1993 and 2016. J Psychopharmacol (in preparation)"},{"key":"1060_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1017\/S1461145711001192","volume":"15","author":"M Letmaier","year":"2012","unstructured":"Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R (2012) Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol 15:739\u2013748. \nhttps:\/\/doi.org\/10.1017\/S1461145711001192","journal-title":"Int J Neuropsychopharmacol"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/archinte.1994.00420100093012","volume":"154","author":"J Avorn","year":"1994","unstructured":"Avorn J, Monane M, Everitt DE, Beers MH, Fields D (1994) Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication. Arch Intern Med 154:1113\u20131117. \nhttps:\/\/doi.org\/10.1001\/archinte.1994.00420100093012","journal-title":"Arch Intern Med"},{"key":"1060_CR40","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","volume":"165","author":"PA Rochon","year":"2005","unstructured":"Rochon PA, Stukel TA, Sykora K et al (2005) Atypical antipsychotics and parkinsonism. Arch Intern Med 165:1882\u20131888. \nhttps:\/\/doi.org\/10.1001\/archinte.165.16.1882","journal-title":"Arch Intern Med"},{"key":"1060_CR41","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/s0140-6736(03)13306-5","volume":"361","author":"S Leucht","year":"2003","unstructured":"Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581\u20131589. \nhttps:\/\/doi.org\/10.1016\/s0140-6736(03)13306-5","journal-title":"Lancet"},{"key":"1060_CR42","first-page":"1","volume":"2","author":"D Jack","year":"2001","unstructured":"Jack D (2001) Dopamine antagonists: phenothiazine\/thioxanthene SAR. Princ Drug Action 2:1\u201314","journal-title":"Princ Drug Action"},{"key":"1060_CR43","first-page":"10","volume":"11","author":"JFM Masso","year":"1996","unstructured":"Masso JFM, Poza JJ (1996) Drug-induced or aggravated parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia 11:10\u201315","journal-title":"Neurologia"},{"key":"1060_CR44","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"JP Zhang","year":"2013","unstructured":"Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmaco 16:1205\u20131218. \nhttps:\/\/doi.org\/10.1017\/S1461145712001277","journal-title":"Int J Neuropsychopharmaco"},{"key":"1060_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"1060_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/0019-5545.130510","volume":"56","author":"N Mandal","year":"2014","unstructured":"Mandal N, Singh OP, Sen S (2014) Extrapyramidal side effects with low doses of amisulpride. Indian J Psychiatry 56:197\u2013199. \nhttps:\/\/doi.org\/10.4103\/0019-5545.130510","journal-title":"Indian J Psychiatry"},{"key":"1060_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/NRL.0000000000000096","volume":"22","author":"K Selfani","year":"2017","unstructured":"Selfani K, Soland VL, Chouinard S, Huot P (2017) Movement disorders induced by the \u201catypical\u201d antipsychotic aripiprazole. Neurologist 22:24\u201328. \nhttps:\/\/doi.org\/10.1097\/NRL.0000000000000096","journal-title":"Neurologist"},{"key":"1060_CR48","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington","edition":"5"},{"key":"1060_CR49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/JCP.0b013e3182a6a2e3","volume":"34","author":"PJ Blanchet","year":"2014","unstructured":"Blanchet PJ, Rompre PH (2014) Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia. J Clin Psychopharmacol 34:36\u201339. \nhttps:\/\/doi.org\/10.1097\/JCP.0b013e3182a6a2e3","journal-title":"J Clin Psychopharmacol"},{"key":"1060_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/jprls.s99197","volume":"6","author":"P Blanchet","year":"2016","unstructured":"Blanchet P, Kivenko V (2016) Drug-induced parkinsonism: diagnosis and management. J Park Restless Legs Syndr 6:83\u201391. \nhttps:\/\/doi.org\/10.2147\/jprls.s99197","journal-title":"J Park Restless Legs Syndr"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-01060-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-019-01060-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-019-01060-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T23:14:50Z","timestamp":1598051690000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-019-01060-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,23]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s00406-019-01060-7","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,23]]},"assertion":[{"value":"8 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Druschky, S. Bleich, R.R. Engel, A. Neyazi, B. D\u00e4ubl, and S. St\u00fcbner: no conflict of interest to be declared; R. Grohmann and S. Toto are project managers of the AMSP programme; S. Toto has been a member of the advisory board for Otsouka and has received speaker\u00b4s honoraria from Janssen\u2212Cilag, Lundbeck, Otsouka and Servier. None. The AMSP drug safety programme is facilitated by nonprofit associations in Germany, Austria and Switzerland. The AMSP programme has been supported with unrestricted educational and research grants since 1993 by the following companies: Austrian companies: Astra Zeneca \u00d6sterreich GmbH, Boehringer Ingelheim Austria, Bristol-Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform, and Wyeth Lederle Pharma GmbH. German companies: Abbott GmbH & Co. KG, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE\u2013O\/R\/N, Bayer Vital GmbH, Boehringer Mannheim GmbH, Bristol-Myers Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Novartis Pharma GmbH, Nordmark Arzneimittel GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Rhone-Poulenc Rohrer, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr. Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH, and Wyeth-Pharma GmbH. Swiss companies: AHP (Schweiz) AG, AstraZeneca AG, Bristol-Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Organon AG, Pfizer AG, Pharmacia, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthelabo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Wyeth AHP (Suisse) AG, and Wyeth Pharmaceuticals AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}